Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Open-label pediatric pharmacokinetic and safety study of Combogesic IV for acute pain
2025-524431-39-00Phase 3Authorised
- Sponsor
- AFT Pharmaceuticals
- Start
- Sep 2026
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 3, open-label, single-arm trial of acetaminophen + ibuprofen, ibuprofen and acetaminophen in acute pain, sponsored by AFT Pharmaceuticals. Primary endpoint: Incidence of treatment-emergent adverse events. Planned start Sep 2026; status: authorised.
02
Drugs
acetaminophen + ibuprofenibuprofenacetaminophen
03
Conditions
acute pain
Beyond the preview
Go deeper on 2025-524431-39-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2025-524431-39-00.